Eric Langer | 10/23/2014
Biopharmaceutical companies that get stuck with legacy technologies, including older stainless steel equipment, and older processes, end up watching as competitors transition to more efficient, cost-effective platforms. But this isn’t just a cost-of-production issue; it goes to more strategic factors like being able to even participate in the emerging biosimilars markets, as well as being able to participate in global emerging economies.
Our 11thAnnual Report of Biopharmace...
To continue reading this story Click Here
RECOMMENDED
Digital Transformation in Pharma: Navigating CMO Partnerships and Supply Chain Resilience
2025-01-22
Sustainability and Inclusivity in Pharma Manufacturing: Insights from AstraZeneca’s People Hub
2024-12-11
Upcoming Events
Pharmaceutical Launch Excellence Summit
2 - 3 December, 2025
UK
Register Now |
View Agenda |
Learn More